Reirradiation and hyperthermia for radiation-associated sarcoma
/in Hyperthermia, International Publications, Soft Tissue Sarcoma /von 2011-06-28 / Cancer 2012 Jan;118(1):180-7A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma
/in Dendritic Cells, Glioblastoma, International Publications /von 2011-06-28 / J Clin Neurosci 2011 Aug;18(8):1048-54Prostate cancer immunotherapy
/in Dendritic Cells, International Publications, Prostate Cancer /von 2011-06-23 / Clin. Cancer Res. 2011 Aug;17(16):5233-8Radiation combined with hyperthermia induces HSP70-dependent maturation of dendritic cells and release of pro-inflammatory cytokines by dendritic cells and macrophages
/in Hyperthermia, International Publications /von 2011-06-23 / Radiother Oncol 2011 Oct;101(1):109-15Dendritic cell (DC) vaccination with low dose temozolomide phase I/II trial in melanoma patients: Preliminary data on peripheral blood regulatory t-cells (Treg) and DC-TEM8 expression modulations.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2011-06-17 / J Clin Oncol 29: 2011 (suppl; abstr e13029)Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer
/in Dendritic Cells, International Publications, NSCLC /von 2011-06-17 / Cancer Immunol. Immunother. 2011 Oct;60(10):1497-502Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study
/in Dendritic Cells, International Publications, NSCLC /von 2011-06-17 / J. Exp. Clin. Cancer Res. 2011 Jun;30:65Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research
/in Dendritic Cells, International Publications, Prostate Cancer /von 2011-06-15 / Clin. Cancer Res. 2011 Jun;17(12):3884-91Recent advances in immunotherapy for the treatment of prostate cancer
/in Dendritic Cells, International Publications, Prostate Cancer /von 2011-06-15 / Expert Opin Biol Ther 2011 Aug;11(8):997-1009
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de